Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.

ABSTRACT:

Background

Urothelial carcinoma is a significant health concern in the United States (US), with high mortality and economic burdens. The CheckMate-901 trial showed promising survival benefits for nivolumab combined with gemcitabine and cisplatin followed by nivolumab maintenance therapy (nivolumab-combination) as first-line treatment of unresectable or metastatic urothelial carcinoma (UC), but its cost-effectiveness is unclear.

Objectives

This study aimed to evaluate the cost-effectiveness of the nivolumab-combination versus standard chemotherapy (gemcitabine-cisplatin) for advanced UC from the perspective of healthcare payers in the US.

Design

A model-based pharmacoeconomic evaluation.

Methods

Based on the CheckMate-901 study, a three-state Markov model (progr

SUBMITTER: Lin J 

PROVIDER: S-EPMC11650468 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature